ESMO Targeted Anticancer Therapies Congress 2020: Industry Participation

TAT congresses are annual meetings on new molecular targets and innovative cancer therapeutics in the early phases of clinical development.

Add to these features the high scientific standards, informal atmosphere, and active participation by the world’s leading phase 1 investigators, and you will understand why the TAT Congress has become the prime international anticancer drug development meeting.

Fast Facts: Targeted Anticancer Therapies Congress 2020

  • Expecting over 400 participants
  • No parallel sessions
  • Possibility to host a satellite symposium
  • More than 60 internationally renowned faculty
  • Excellent networking opportunities

Past attendance

ESMO gratefully acknowledges the valuable contribution of the following organisations in the TAT Congresses over the years.

Past attendees
4clinics Celgene France MSD
AbbVie Daiichi Sankyo Cancer Enterprise Novartis
Active Motif ESMO Orion Pharma
Adaptive Biotechnologies GSK Pfizer
Amgen Illumina PharmaMar
Amoy Diagnostics Co, Ltd. Innate Pharma Pierre Fabre
Astex Pharmaceuticals, Inc. INC Roche
AstraZeneca France Incyte Corporation Sanofi
AstraZeneca MedImmune Immodulon Therapeutics Servier Oncology
Bavarian Nordic Ipsen Pharma Syneos Health
Bayer Janssen Pharmaceutical Research & Development, L.C.C. SIRIC-SOCRATE
BlueDNAcompanion Lilly Takeda
Boehringer Ingelheim Merck Tesaro
Bristol-Myers Squibb MedImmune  

How can I participate in ESMO Targeted Anticancer Therapies Congress 2020?

At ESMO we are committed to providing our industry partners with a variety of solutions to facilitate their presence at our congress.

Contact the ESMO Strategic Partnerships Team for more details. We look forward to hearing from you!

Who has already signed up?

ESMO gratefully acknowledges the valuable contribution the following organisations have made to the Targeted Anticancer Therapies Congress 2020. (As of October 2019):

Platinum Sponsor

Roche logo

Silver Sponsor


Bronze Sponsors